The efficacy of botulinum toxin type A in the treatment of Hailey–Hailey disease
(Source: Dermatologic Therapy)
Source: Dermatologic Therapy - March 11, 2016 Category: Dermatology Authors: Nooshin Bagherani, Bruce R. Smoller Tags: Journal Highlights Source Type: research

The efficacy of botulinum toxin type A in the treatment of Hailey –Hailey disease
(Source: Dermatologic Therapy)
Source: Dermatologic Therapy - March 11, 2016 Category: Dermatology Authors: Nooshin Bagherani, Bruce R. Smoller Tags: Journal Highlights Source Type: research

Botulinum Toxin and Muscle Atrophy: A Wanted or Unwanted Effect
While the facial rejuvenating effect of botulinum toxin type A is well known and widespread, its use in body and facial contouring is less common. We first describe its use for deliberate muscle volume reduction, and then document instances of unanticipated and undesirable muscle atrophy. Finally, we investigate the potential long-term adverse effects of botulinum toxin-induced muscle atrophy. Although the use of botulinum toxin type A in the cosmetic patient has been extensively studied, there are several questions yet to be addressed. Does prolonged botulinum toxin treatment increase its duration of action? What is the m...
Source: Aesthetic Surgery Journal - March 9, 2016 Category: Cosmetic Surgery Authors: Durand, P. D., Couto, R. A., Isakov, R., Yoo, D. B., Azizzadeh, B., Guyuron, B., Zins, J. E. Tags: Special Topic Source Type: research

Evaluation of group versus individual physiotherapy following lower limb intra-muscular Botulinum Toxin-Type A injections for ambulant children with cerebral palsy: A single-blind randomized comparison trial
This study aimed to evaluate efficacy of group (GRP) versus individual (IND) physiotherapy rehabilitation following lower limb intramuscular injections of Botulinum Toxin-Type A (BoNT-A) for ambulant children with cerebral palsy (CP). Following lower limb BoNT-A injections, 34 children were randomly allocated to GRP (n =17; mean age 7y8m SD 2.0; 13 males; Gross Motor Function Classification System (GMFCS) I=5, II=8, III=4) or IND physiotherapy (n =17; mean age 8y7m SD 2.0; 11 males; GMFCS I=9, II=5, III=3). Primary outcomes were the Canadian Occupational Performance Measure (COPM) and Edinburgh Visual Gait Score (EVGS) ass...
Source: Research in Developmental Disabilities - March 7, 2016 Category: Disability Source Type: research

Alteration of Skin Mechanical Properties in Patients Undergoing Botulinum Toxin Type A Injections of Forehead Rhytides
Conclusions We concluded that intramuscular injections of BTX-A significantly regulated the gross elasticity, net elasticity, functional elasticity and viscoelastic elasticity at the injection point over a radius of 1.5 cm at 2, 4 and 8 weeks follow-up. The alteration in the skin measurements had completely diminished by the 16-week follow-up. Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instruc...
Source: Aesthetic Plastic Surgery - March 4, 2016 Category: Cosmetic Surgery Source Type: research

Role of Botulinum Toxin in Depression
Conclusions: This study suggests that botulinum toxin A can produce significant improvement in depressive symptoms and is a safe adjunctive treatment for patients receiving pharmacotherapy for depression. Future trials are needed to evaluate the antidepressant effect per se of botulinum toxin A and to further elucidate the underlying antidepressant mechanism of botulinum toxin A. (Source: Journal of Psychiatric Practice)
Source: Journal of Psychiatric Practice - March 1, 2016 Category: Psychiatry Tags: Articles Source Type: research

Comparison of extracorporeal shock wave therapy with botulinum toxin type A in the treatment of plantar fasciitis.
Abstract Objective To compare the efficacy of extracorporeal shock wave therapy (ESWT) with botulinum toxin type A (BoNT-A) in the treatment of plantar fasciitis (PF). Design Open label, prospective, randomized study. Results A total of 72 patients were included. In all participants the median (and interquartile range) of the visual analog scale (VAS) of pain result, when taking the first steps, was 8 (6-9) points before treatment and 6 (4-8) points after treatment (p 
Source: Disability and Rehabilitation - March 1, 2016 Category: Rehabilitation Authors: Roca B, Mendoza MA, Roca M Tags: Disabil Rehabil Source Type: research

Increasing the survival of transverse rectus abdominis musculocutaneous flaps with a Botulinum Toxin-A Injection: A comparison of surgical and chemical flap delay methods
In this study, we used a rat transverse rectus abdominis musculocutaneous (TRAM) flap model to examine the effects of Btx-A on the skin island, which is perfused by the rectus abdominis muscle according to the angiosome concept. (Source: Journal of Plastic, Reconstructive and Aesthetic Surgery)
Source: Journal of Plastic, Reconstructive and Aesthetic Surgery - February 29, 2016 Category: Cosmetic Surgery Authors: Gökhan Temiz, Nebil Yeşiloğlu, Hakan Şirinoğlu, Ali Cem Akpınar, Murat Sarıcı, Deniz Filinte, Gaye Taylan Filinte, Mehmet Bozkurt Source Type: research

Global Aesthetics Consensus: Botulinum Toxin Type A—Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications
Conclusions: The accumulation of clinical evidence and experience with botulinum toxin has led to refinements in treatment planning and implementation. The Global Aesthetics Consensus Group advocates an etiology-driven, patient-tailored approach, to enable achievement of optimal efficacy and safety in patient populations that are rapidly diversifying with respect to ethnicity, gender, and age. CLINCAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, V. (Source: Plastic and Reconstructive Surgery)
Source: Plastic and Reconstructive Surgery - February 27, 2016 Category: Cosmetic Surgery Tags: Cosmetic: Original Articles Source Type: research

A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia
Abstract A systematic pair-wise comparison of all available botulinum toxin serotype A and B treatments for cervical dystonia (CD) was conducted, as direct head-to-head clinical trial comparisons are lacking. Five botulinum toxin products: Dysport® (abobotulinumtoxinA), Botox® (onabotulinumtoxinA), Xeomin® (incobotulinumtoxinA), Prosigne® (Chinese botulinum toxin serotype A) and Myobloc® (rimabotulinumtoxinB) have demonstrated efficacy for managing CD. A pair-wise efficacy and safety comparison was performed for all toxins based on literature-reported clinical outcomes. Multi-armed randomized c...
Source: Journal of Neurology - February 25, 2016 Category: Neurology Source Type: research

Effects of botulinum toxin type A facial injection on monoamines and their metabolites in sensory, limbic and motor brain regions in rats
Publication date: 23 March 2016 Source:Neuroscience Letters, Volume 617 Author(s): S. Ibragić, I. Matak, A. Dračić, A. Smajlović, M. Muminović, F. Proft, E. Sofić, Z. Lacković, P. Riederer Despite its toxicity, botulinum neurotoxin type A (BTX-A) is a valuable therapeutic agent for several motor, autonomic and pain disorders. Numerous studies have described its peripheral as well as central effects. Using reversed-phase High Performance Liquid Chromatography with Electrochemical Detection (HPLC-ED) and gradient elution, we quantified the concentrations of dopamine (DA), noradrenaline (NA), serotonin (5-HT...
Source: Neuroscience Letters - February 24, 2016 Category: Neuroscience Source Type: research

Can botox improve night‐time overactive bladder symptoms in women?
AimsDespite the efficacy of intravesical onabotulinumtoxinA (Botox) therapy for urgency, urgency incontinence, and daytime frequency, its value in treatment of nocturia remains unclear. The aim of the prospective observational study was to assess the effect of onabotulinumtoxinA on night‐time symptoms in women with overactive bladder (OAB), including nocturia, night‐time urgency incontinence, and nocturnal voided volume as end‐points. MethodsWomen with idiopathic OAB (with at least one episode of urgency urinary incontinence (UUI) per day, ≥8 micturitions per 24 hr, and ≥2 nocturia episodes per night) we...
Source: Neurourology and Urodynamics - February 24, 2016 Category: Urology & Nephrology Authors: Pawel Miotla, Rufus Cartwright, Konrad Futyma, Michal Bogusiewicz, Katarzyna Skorupska, Izabela Winkler, Tomasz Rechberger Tags: Original Clinical Article Source Type: research

Can botox improve night ‐time overactive bladder symptoms in women?
AimsDespite the efficacy of intravesical onabotulinumtoxinA (Botox) therapy for urgency, urgency incontinence, and daytime frequency, its value in treatment of nocturia remains unclear. The aim of the prospective observational study was to assess the effect of onabotulinumtoxinA on night‐time symptoms in women with overactive bladder (OAB), including nocturia, night‐time urgency incontinence, and nocturnal voided volume as end‐points. MethodsWomen with idiopathic OAB (with at least one episode of urgency urinary incontinence (UUI) per day, ≥8 micturitions per 24 hr, and ≥2 nocturia episodes per night) we...
Source: Neurourology and Urodynamics - February 24, 2016 Category: Urology & Nephrology Authors: Pawel Miotla, Rufus Cartwright, Konrad Futyma, Michal Bogusiewicz, Katarzyna Skorupska, Izabela Winkler, Tomasz Rechberger Tags: Clinical Article Source Type: research

A pharmacological treatment algorithm for localized neuropathic pain.
Authors: Allegri M, Baron R, Hans G, Correa-Illanes G, Mayoral Rojals V, Mick G, Serpell M Abstract Neuropathic pain is caused by a lesion or disease affecting the somatosensory system and is difficult to manage, often proving refractory to existing treatments. In more than half of cases, it is localized and affects a specific, clearly circumscribed area of the body (localized neuropathic pain, or LNP). A recently developed screening tool enables patients with probable neuropathic pain/LNP to be identified quickly and easily. In view of the conflicting current treatment recommendations, an advisory board of pain sp...
Source: Current Medical Research and Opinion - February 18, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research

Sonographic and clinical effects of botulinum toxin Type A combined with extracorporeal shock wave therapy on spastic muscles of children with cerebral palsy
10.3109/17518423.2015.1105320Alessandro Picelli (Source: Developmental Neurorehabilitation)
Source: Developmental Neurorehabilitation - February 18, 2016 Category: Neurology Authors: Alessandro PicelliElisabetta La MarchinaFrancesca GajofattoAngelo PontilloAntonella VangelistaRoberto FilippiniAlessio BaricichCarlo CisariNicola Smania Source Type: research

Sonographic and clinical effects of botulinum toxin Type A combined with extracorporeal shock wave therapy on spastic muscles of children with cerebral palsy
. (Source: Developmental Neurorehabilitation)
Source: Developmental Neurorehabilitation - February 18, 2016 Category: Neurology Authors: Alessandro Picelli Elisabetta La Marchina Francesca Gajofatto Angelo Pontillo Antonella Vangelista Roberto Filippini Alessio Baricich Carlo Cisari Nicola Smania Source Type: research

Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States
Abstract Botulinum toxin, also known as Botox, is produced by Clostridium botulinum, a gram-positive anaerobic bacterium, and botulinum toxin injections are among the most commonly practiced cosmetic procedures in the USA. Although botulinum toxin is typically associated with cosmetic procedures, it can be used to treat a variety of other conditions, including pain. Botulinum toxin blocks the release of acetylcholine from nerve endings to paralyze muscles and to decrease the pain response. Botulinum toxin has a long duration of action, lasting up to 5 months after initial treatment which makes it an excellen...
Source: Current Pain and Headache Reports - February 15, 2016 Category: Neurology Source Type: research

Treatment of allergic rhinitis with intranasal infusion of botulinum toxin type A in mice
Conclusions Topical treatment with BTX-A efficiently and temporarily ameliorates AR symptoms. Intranasal infusion does not cause pain or bleeding, and the effects of a single infusion of BTX-A last for at least three weeks. This treatment might be a promising therapeutic strategy for the treatment of AR. (Source: Life Sciences)
Source: Life Sciences - February 11, 2016 Category: Biology Source Type: research

Botulinum Toxin to Treat Neurogenic Bladder
Semin Neurol 2016; 36: 005-009DOI: 10.1055/s-0035-1571216Alteration in neural control from suprapontine areas to the nerves innervating the bladder can lead to bladder dysfunction and the development of a neurogenic bladder (NGB). Patients with NGB often suffer from urinary incontinence, which can lead to adverse events such as urinary tract infections and decubiti, in addition to creating a large care burden for family members or healthcare providers and significantly impairing patient quality of life. The common failure of anticholinergic medications has spurned the development of second-line treatments, including the us...
Source: Seminars in Neurology - February 11, 2016 Category: Neurology Authors: Smith, Christopher P.Chancellor, Michael B. Source Type: research

The Use of Botulinum Toxin in the Management of Headache Disorders
Semin Neurol 2016; 36: 092-098DOI: 10.1055/s-0036-1571443Headache disorders can be further classified as episodic (
Source: Seminars in Neurology - February 11, 2016 Category: Neurology Authors: Silberstein, Stephen D. Source Type: research

Abdominal Cramping as a symptom of benign fasciculation syndrome with an excellent response to botulinum toxin
Conclusion This patient shows that in cases of BFS, localized cramps can be successfully treated with low doses of botulinum toxin. (Source: Basal Ganglia)
Source: Basal Ganglia - February 10, 2016 Category: Neurology Source Type: research

Outcomes of Botulinum Toxin Type A Injection Followed by Rehabilitation in Cases of Cerebral Palsy With Upper Extremity Involvement
We evaluated the efficiency of botulinum toxin type A injection followed by a rehabilitation program including individual therapy, group therapy, and occupational therapy in cases of cerebral palsy with upper extremity involvement. A total of 29 injections were performed on 25 patients, and the patients were placed on rehabilitation program. At 3-month and 6-month assessments, there was a significant improvement in lateral grip strength, 9 Hole Peg test, Upper Limb Physician’s Rating Scale and pediatric functional independence measure total scores. There were significant decreases in active range of motion in elbow e...
Source: Journal of Child Neurology - February 9, 2016 Category: Neurology Authors: Karaca, B., Ünlü, E., Köse, G., Gönen, E., Cakcı, A. Tags: Original Articles Source Type: research

Botulinum Toxin Type A Injection for Spastic Equinovarus Foot in Children with Spastic Cerebral Palsy: Effects on Gait and Foot Pressure Distribution.
CONCLUSION: Using a computerized gait analysis and foot scan, this study revealed significant benefits of BoNT-A injection into the GCM and TP muscles for dynamic equinovarus foot in children with spastic CP. PMID: 26847306 [PubMed - in process] (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - February 8, 2016 Category: Universities & Medical Training Authors: Choi JY, Jung S, Rha DW, Park ES Tags: Yonsei Med J Source Type: research

Botulinum Toxin Treatment of Essential Tremor - A Customized Approach (S27.002)
CONCLUSIONS: This customized, blinded, EMG-guided injection study of incobotulinumtoxinA produced statistically significant improvement of tremor and patient satisfaction. Unacceptable hand weakness occurred in a small percentage of patients. This treatment should be considered for patients with continued bothersome ET despite use of oral medications.Disclosure: Dr. Rostami has nothing to disclose. Dr. Chow has nothing to disclose. Dr. Richardson has nothing to disclose. Dr. Jabbari has received research support from Allergan Inc, Merz Pharmaceuticals, and Ipsen Pharmaceuticals. Dr. Machado has nothing to disclose. (Source: Neurology)
Source: Neurology - February 8, 2016 Category: Neurology Authors: Rostami, R., Chow, C., Richardson, D., Jabbari, B., Machado, D. Tags: Movement Disorders. Essential Tremor and Tardive Dyskinesia Source Type: research

Intravesical electromotive botulinum toxin type A administration for management of concomitant neuropathic bowel and bladder dysfunction in children
(Source: International Journal of Colorectal Disease)
Source: International Journal of Colorectal Disease - February 4, 2016 Category: Gastroenterology Source Type: research

Botulinum Toxin Type A for Relief of Intractable Pain After Face and Brow-Lift Surgery
No abstract available (Source: Dermatologic Surgery)
Source: Dermatologic Surgery - February 1, 2016 Category: Dermatology Tags: Letters and Communications Source Type: research

Comparison of Effects of Botulinum Toxin Injection Between Subacute and Chronic Stroke Patients: A Pilot Study
In conclusion, botulinum toxin injection in subacute patients was more helpful for spasticity, contracture, and function than in chronic patients. However, beneficial effects of botulinum toxin injection on spasticity and function in chronic patients were found in the assessments of the modified Tardieu scale and Fugl-Meyer scale. (Source: Medicine)
Source: Medicine - February 1, 2016 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Use of Botox (OnabotulinumtoxinA) for the Treatment of Parotid Sialocele and Fistula After Extirpation of Buccal Squamous Cell Carcinoma With Immediate Reconstruction Using Microvascular Free Flap: A Report of 3 Cases
Buccal squamous cell carcinoma is an aggressive form of oral carcinoma with a high recurrence rate. Injury to the parotid duct is often unavoidable when surgically treating buccal squamous cell carcinoma because of the intimate anatomic relation among the buccal mucosa, Stensen duct, and parotid gland. It is often difficult to achieve negative margins and preserve the integrity of the parotid duct. Sialocele formation is a frequent and untoward complication owing to extravasation of saliva into the surgical defect, which delays healing, creates fistulas, and produces painful facial swelling. (Source: Journal of Oral and Maxillofacial Surgery)
Source: Journal of Oral and Maxillofacial Surgery - January 28, 2016 Category: ENT & OMF Authors: James C. Melville, Daniel J. Stackowicz, Jonathon S. Jundt, Jonathan W. Shum Tags: Surgical oncology and reconstruction Source Type: research

Botulinum Toxin Type A for Neuropathic Pain in Patients with Spinal Cord Injury
This article is protected by copyright. All rights reserved. (Source: Annals of Neurology)
Source: Annals of Neurology - January 27, 2016 Category: Neurology Authors: Zee‐A Han, Dae Heon Song, Hyun‐Mi Oh, Myung Eun Chung Tags: Research Article Source Type: research

Comparison of clinical marking and ultrasound ‐guided injection of Botulinum type A toxin into the masseter muscles for treating bruxism and its cosmetic effects
ConclusionsUltrasound can be a potent tool for guiding the injection of Botulinum toxin into the masseter muscles. It may contribute to a more personalized procedure, better cosmetic results, and help to avoid potential complications. (Source: Journal of Cosmetic Dermatology)
Source: Journal of Cosmetic Dermatology - January 22, 2016 Category: Dermatology Authors: Natacha Quezada ‐Gaon, Ximena Wortsman, Osvaldo Peñaloza, Juan Eduardo Carrasco Tags: Original Contribution Source Type: research

Efficacy of botulinum toxin type A 100 units versus 200 units for treatment of refractory idiopathic overactive bladder
Conclusion: A single-injection procedure of 100 U or 200 U BoNTA is an effective and safe treatment for patients with IOAB who failed anticholinergic regimens. OABSS and QoL were improved for 6 months; 100 U injections seemed to have comparable results with 200 U. There was a significant difference at month 9 towards 200 U with more incidences of adverse events. (Source: International Braz J Urol)
Source: International Braz J Urol - January 20, 2016 Category: Urology & Nephrology Source Type: research

Endoluminal Bariatric Interventions: Where do we stand ? Where are we going ?
CONCLUSION: Endoluminal bariatric techniques can become the primary choice of therapy in the near future for bariatric care. PMID: 26712053 [PubMed - in process] (Source: Acta Gastro-Enterologica Belgica)
Source: Acta Gastro-Enterologica Belgica - January 15, 2016 Category: Gastroenterology Tags: Acta Gastroenterol Belg Source Type: research

Botulinum toxin type A as treatment of partially accommodative esotropia.
CONCLUSION: Botulinum toxin type A is an effective long-term treatment with a good response in 71.43% of patients. No predictors of good response were demonstrated. PMID: 26747023 [PubMed - as supplied by publisher] (Source: Archivos de la Sociedad Espanola de Oftalmologia)
Source: Archivos de la Sociedad Espanola de Oftalmologia - January 13, 2016 Category: Opthalmology Tags: Arch Soc Esp Oftalmol Source Type: research

Toe walking: causes, epidemiology, assessment, and treatment
Purpose of review: The present review includes the most up-to-date literature on the causes, epidemiology, diagnosis, and treatment of toe walking. Recent findings: The prevalence of toe walking at age 5.5 years is 2% in normally developing children, and 41% in children with a neuropsychiatric diagnosis or developmental delays. A recent systematic review concluded that there is good evidence for casting and surgery in the treatment of idiopathic toe walking, with only surgery providing long-term results beyond 1 year. Botox combined with casting does not provide better outcomes compared with casting alone. Ankle-foot-orth...
Source: Current Opinion in Pediatrics - January 13, 2016 Category: Pediatrics Tags: ORTHOPEDICS: Edited by Daniel W. Green Source Type: research

Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity
This retrospective study aimed to compare the therapeutic response, including side effects, for oral baclofen versus oral tizanidine therapy with adjuvant botulinum toxin type A in a group of 64 pediatric patients diagnosed with static encephalopathy and spastic equinus foot deformity. Following botulinum toxin A treatment, clinical improvement led to the gradual reduction of baclofen or tizanidine dosing to one-third of the former dose. Gross Motor Functional Measure and Caregiver Health Questionnaire scores were markedly elevated post–botulinum toxin A treatment, with scores for the tizanidine (Gross Motor Function...
Source: Journal of Child Neurology - January 12, 2016 Category: Neurology Authors: Dai, A. I., Aksoy, S. N., Demiryürek, A. T. Tags: Original Articles Source Type: research

Recalcitrant Hailey-Hailey Disease Responds to Oral Tacrolimus and Botulinum Toxin Type A
To the Editor: Hailey-Hailey disease, also known as familial benign pemphigus, is a chronic blistering skin disorder that typically presents as a recurrent vesicular or bullous dermatitis found... (Source: Cutis: Cutaneous Medicine for the Practitioner)
Source: Cutis: Cutaneous Medicine for the Practitioner - January 11, 2016 Category: Dermatology Source Type: research

Sensorimotor Modulation by Botulinum Toxin A in Post-Stroke Arm Spasticity: Passive Hand Movement
In post-stroke spasticity, functional imaging may uncover modulation in the central sensorimotor networks associated with botulinum toxin type A (BoNT) therapy. Investigations were performed to localize brain activation changes in stroke patients treated with BoNT for upper limb spasticity using functional magnetic resonance imaging (fMRI). (Source: Journal of the Neurological Sciences)
Source: Journal of the Neurological Sciences - January 11, 2016 Category: Neurology Authors: Tomáš Veverka, Petr Hluštík, Pavel Hok, Pavel Otruba, Jana Zapletalová, Zbyněk Tüdös, Alois Krobot, Petr Kaňovský Source Type: research

Review of quality of patient information regarding Botox cosmetic on the internet
One of the world's most popular and widely used cosmetic treatments is Botox®.1,2 It is injected into facial muscles in order to temporarily improve the appearance of moderate to severe frown lines and crow's feet lines in adults. The popularity of Botox® treatments is manifested in the large number of patients searching for information on Internet for indications, costs, effects and good practitioners, prior to consulting a health professional. (Source: Journal of Plastic, Reconstructive and Aesthetic Surgery)
Source: Journal of Plastic, Reconstructive and Aesthetic Surgery - January 6, 2016 Category: Cosmetic Surgery Authors: Francesca Romana Grippaudo, Matteo Atzeni, Fabio Santanelli di Pompeo Tags: Correspondence and communication Source Type: research

Chronic orchialgia: Review of treatments old and new
Conclusion: Chronic orchialgia has been and will continue to be a challenging disease to treat due to its multiple etiologies and variable treatment outcomes. Further studies are needed to better understand the problem. Treatment options for patients with chronic orchialgia are improving. Additional studies are warranted to better understand the long-term durability of this treatment options. (Source: Indian Journal of Urology)
Source: Indian Journal of Urology - January 4, 2016 Category: Urology & Nephrology Authors: Bayo TojuolaJeffrey LaymanIbrahim KartalAhmet GudelogulJamin BrahmbhattSijo Parekattil Source Type: research

Peyronie's disease: What's around the bend?
Conclusions: Further research is essential to develop novel, safe, and effective minimally invasive PD treatment options. This work is ongoing, with the promise of specific, targeted, and highly effective therapies on the horizon. (Source: Indian Journal of Urology)
Source: Indian Journal of Urology - January 4, 2016 Category: Urology & Nephrology Authors: Aylin N BilgutayAlexander W Pastuszak Source Type: research

Effective local anesthesia for onabotulinumtoxin A injections to treat hyperhidrosis associated with traumatic amputation. Shi, Lucy L; Sargen, Michael R; Chen, Suephy C; Arbiser, Jack L; Pollack, Brian P
Background: Botulinum toxin type A (BTX-A) injections are an effective treatment for controlling hyperhidrosis at sites of amputation. Hyperesthesia associated with amputated limbs is a major barrier to performing this procedure under local anesthesia. Objective: To present a novel method for improving local anesthesia with BTX-A injections. Methods & Results: A 29-year-old military veteran with a below-the-knee amputation of his right leg was suffering from amputation site hyperhidrosis, which was impeding his ability to comfortably wear a prosthesis. Prior to presenting to our clinic, the patient ...
Source: Dermatology Online Journal - January 1, 2016 Category: Dermatology Source Type: research

Relationship Between Botulinum Toxin, Spasticity, and Pain: a Survey of Patient Perception.
CONCLUSIONS: The high incidence of pain noted within our sample suggests that physicians may have to consider pain management as part of spasticity treatment. Participants reported that their pain was related to their spasticity, and that it decreased after BoNTA treatment. Further study is needed to explore the relationships between objective measures of spasticity and pain. PMID: 26691344 [PubMed - as supplied by publisher] (Source: The Canadian Journal of Neurological Sciences)
Source: The Canadian Journal of Neurological Sciences - December 22, 2015 Category: Neurology Authors: Shaikh A, Phadke CP, Ismail F, Boulias C Tags: Can J Neurol Sci Source Type: research

Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches
Conclusions and ImplicationsPericranially injected BoNT/A was taken up by local sensory nerve endings, axonally transported to the trigeminal ganglion and transcytosed to dural afferents. Colocalization of cleaved SNAP‐25 and the migraine mediator CGRP in dura suggests that BoNT/A may prevent DNI by suppressing transmission by CGRP. This might explain the effects of BoNT/A in temporomandibular joint inflammation and in migraine and some other headaches. (Source: British Journal of Pharmacology)
Source: British Journal of Pharmacology - December 19, 2015 Category: Drugs & Pharmacology Authors: Zdravko Lacković, Boris Filipović, Ivica Matak, Zsuzsanna Helyes Tags: RESEARCH PAPER Source Type: research

Adherence to Oral Therapy for Urgency Urinary Incontinence: Results from the Anticholinergic Versus Botox Comparison (ABC) Trial
Conclusions: Adherence using pill counts and MEMSCAP was reasonably correlated and similar in both the AC and P groups. In the AC group, higher baseline incontinence severity and better UUI Quality of Life were associated with decreased adherence. Smokers were less adherent. (Source: Female Pelvic Medicine and Reconstructive Surgery)
Source: Female Pelvic Medicine and Reconstructive Surgery - December 18, 2015 Category: OBGYN Tags: Original Articles Source Type: research

Are we following an algorithm for managing chronic anal fissure? A completed audit cycle
Conclusions Topical creams were the most successful treatments (50%; n = 9/18) in ACPGBI-compliant strategies. Importantly, these data suggests that compliance with the ACPGBI algorithm leads to healing without surgery in 83.3% (n = 15/18) of patients, compared to 26.1% (n = 6/23) with non-compliant methods (P = 0.0004). This highlights the benefit of early conservative and medical management of CAF, before attempting surgery. (Source: Annals of Medicine and Surgery)
Source: Annals of Medicine and Surgery - December 18, 2015 Category: Journals (General) Source Type: research

Safety and Efficacy of Botulinum Toxin A in Children Undergoing Lower Limb Lengthening and Deformity Correction: Results of a Double-blind, Multicenter, Randomized Controlled Trial
Conclusions: The clinical differences in quality of life, the lower pain on the first postoperative day, and the lower number of pin-site infections in the tibia favoring BTX-A support its use as an adjunctive treatment to the lengthening process. The detailed analyses of pain patterns help inform families on the pain expectations during lower limb lengthenings. The amount of adverse events were no different in both groups, and bone healing rates were similar, indicating that the use of BTX-A in children undergoing limb lengthening and deformity correction is safe. Level of Evidence: Level I. (Source: Journal of Pediatric Orthopaedics)
Source: Journal of Pediatric Orthopaedics - December 8, 2015 Category: Orthopaedics Tags: Limb Lengthening Source Type: research

Botulinum neurotoxin type A in the treatment of classical Trigeminal Neuralgia (BoTN): study protocol for a randomized controlled trial
DiscussionBoTN is designed to assess the efficacy and safety of subcutaneous botulinum toxin type A injections in addition to standard prophylactic treatment in therapy-refractory trigeminal neuralgia.Trial registration numberEU Clinical Trials Register: EudraCT-No: 2014-001959-24 https://www.clinicaltrialsregister.eu/ctr-search/rest/download/trial/2014-001959-24/DEDate of trial registration26 August 2014 (Source: Trials)
Source: Trials - December 3, 2015 Category: Journals (General) Authors: Jan BurmeisterDagny HolleEva BockClaudia OseHans-Christoph DienerMark Obermann Source Type: research

Contralateral botulinum injections in patients with residual facial asymmetry and contralateral hyperkinesis after primary facial palsy surgery.
CONCLUSIONS: Contralateral botulinum toxin type A injection was useful in reducing muscular hyperkinesis in patients with residual facial asymmetry after primary surgery for facial palsy, improving aesthetic and functional facial recovery with not widely common adverse events. KEY WORDS: Botulinum toxin type A, Contralateral muscular hyperkinesis, Facial palsy. PMID: 26229045 [PubMed - in process] (Source: Annali Italiani di Chirurgia)
Source: Annali Italiani di Chirurgia - December 2, 2015 Category: Surgery Tags: Ann Ital Chir Source Type: research

Use of botulinum toxin type A in symptomatic accessory soleus muscle: first five cases
We describe five patients presenting peri/retromalleolar exertional pain and a contractile muscle mass in the painful region. Com‐pression neuropathy was ruled out by electromyo‐graphic analysis of the lower limb muscles. Doppler ultrasonography was normal, excluding a local vascular compression. ASM was confirmed by magnetic resonance imaging. After a treadmill stress test, abnormal intramuscular pressure values in the ASM, confirmed the diagnosis of compartment syndrome only in one patient. All five patients received BTX‐A injections in two points of the ASM. The treatment efficacy was evaluated based on the d...
Source: Scandinavian Journal of Medicine and Science in Sports - December 1, 2015 Category: Sports Medicine Authors: M‐E. Isner‐Horobeti, G. Muff, E. Lonsdorfer‐Wolf, C. Deffinis, J. Masat, F. Favret, S. P. Dufour, J. Lecocq Tags: Original Article Source Type: research